ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Exploring the efficacy of a novel cannabidiol and bevacizumab combination in non-small cell lung cancer.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality worldwide. Despite advances in therapeutic strategies, the 5-year survival rate for patients with non-small cell lung cancer (NSCLC) remains approximately 15%, highlighting the need for novel and more effective treatment approaches.
objectivesThe present study aimed to investigate the anticancer effects of a cannabidiol and bevacizumab combination in human NSCLC and to elucidate its underlying molecular mechanisms using the A549 cell line as an in vitro model.
methodsA549 cells were cultured and treated with cannabidiol, bevacizumab, or their combination. Cell proliferation was assessed using the MTT assay, while apoptosis was quantified by flow cytometry. The expression of apoptosis-related proteins was evaluated by Western blotting, and the mRNA expression levels of metastasis-associated genes were analyzed using quantitative polymerase chain reaction (qPCR).
resultsCannabidiol, bevacizumab, and their combination inhibited A549 cell proliferation in a dose-dependent manner. The apoptotic rate was 15.23% ± 0.42 following cannabidiol treatment and 21.97% ± 0.50 following bevacizumab treatment. Notably, combined treatment significantly increased apoptosis to 50.47% ± 0.67 (p < 0.001). Western blotting demonstrated that co-treatment markedly downregulated the anti-apoptotic protein Bcl-2 and upregulated the pro-apoptotic protein caspase-9 (p < 0.001). Furthermore, compared with either agent alone, combination therapy significantly reduced the expression of the metastasis-associated genes MMP-2 and MMP-9 (p < 0.001).
conclusionThe combination of cannabidiol and bevacizumab exerts a significantly enhanced anticancer effect on NSCLC cell growth inhibition compared with either agent alone, suggesting a promising therapeutic strategy for the management of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.